MedPath

Evaluation of topical sylimarin formulation efficacy in prevention of radiotherapy induced skin reactions in breast cancer patients

Phase 3
Recruiting
Conditions
Radiodermatitis.
Radiodermatitis, unspecified
Registration Number
IRCT2016110730760N1
Lead Sponsor
Vice chancellor for research, Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
40
Inclusion Criteria

Age above 18 years; Breast cancer patients after mastectomy undergoing radiotherapy; X-ray total dose of 50.4 GY

Exclusion criteria: Diabetes; Smoking; Anti inflammatory drugs; Immunosuppressor drugs; Immunodeficiency diseases; Connective tissue diseases

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Radiodermatitis occurrence. Timepoint: 1 week after intervention,2week after intervention,3week after intervention,4week after intervention,5week afterintervention. Method of measurement: NCI CTCAE version 4.03 and Acute Radiation Morbidity Scoring Criteria (RTOG).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath